Aceon aces supplemental review
Solvay/CV Therapeutics' ACE inhibitor Aceon (perindopril) receives sNDA approval Aug. 23 for treatment of patients with stable coronary artery disease. Aceon was previously approved for treatment of essential hypertension. Solvay was granted priority review following its December sNDA submission, but FDA instituted a three-month extension in June to allow for additional audits of trial sites from the 12,000-patient European trial...
You may also be interested in...
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.